Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. Mito-carboxy proxyl (Mito-CP), a lipophilic cationic nitroxide, accumulates in the mitochondria because of the large negative transmembrane potential. Studies have shown that these agents act by disrupting the energy-producing mechanism, inducing mitochondrial-mediated apoptosis, and also enhancing the action of other chemotherapeutic agents in cancer cells. We hypothesized that the combination of Mito-CP and glycolysis inhibitor, 2-deoxyglucose (2-DG), would synergistically inhibit HCC in vitro. HepG2 cells and primary hepatocytes were treated with various combinations of Mito-CP and 2-DG. Cell cytotoxicity was measured using the methylthiazolyldiphenyl-tetrazolium bromide assay and ATP bioluminescence assay. In addition, caspase 3/7 enzymatic activity was examined after treatment. Mito-CP and 2-DG induced synergistic cytotoxicity in HepG2 cells in a dose-dependent and time-dependent manner, whereas primary cells remained viable and unaffected after treatment. The intracellular ATP levels of HepG2 cells were suppressed within 6 h of combination treatment, whereas primary cells maintained higher levels of ATP. Dose-dependent increases in caspase 3/7 activity occurred in HepG2 cells in a time-dependent manner, showing the initiation of cell death through the apoptotic pathway. These findings indicate that a combination of Mito-CP and 2-DG effectively inhibits HCC growth in vitro. The increase in caspase 3/7 activity supports the occurrence of 2-DG-induced and Mito-CP-induced apoptotic death in HCC. The inability of the compounds to induce cytotoxicity or suppress the production of ATP in primary hepatocytes provides a selective and synergistic approach for the treatment of HCC.
Introduction
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide. The major clinical risk factor for the development of HCC is cirrhosis of the liver. Chronic infections with hepatitis B virus, hepatitis C virus, and increased alcohol consumption are major risk factors that can cause cirrhosis of the liver [1] . Early-stage HCC is frequently asymptomatic; therefore, the disease is detected primarily at an intermediate or an advanced stage. At this stage, most patients are not eligible to undergo surgical interventions of liver resection or orthotopic liver transplantation [2] . Moreover, there has been a significant increase in the incidence of HCC in the past decade. These factors have contributed toward the growing need for the development of innovative and effective treatment methodologies for the treatment of HCC [3] .
A significant difference in the metabolism of cancer cells and normal cells was discovered by Otto Warburg during the 20th century [4] . Warburg [5] postulated that cancer cells, unlike normal cells, rely on glycolysis for most of their energy needs (ATP) to compensate for the loss that occurs because of defective oxidative phosphorylation in the mitochondria. Agents that exploit this mechanism and selectively inhibit glycolytic metabolism have been tested for their anticancer potential in cellular systems and animal models [6, 7] . 2-Deoxyglucose (2-DG) is one such agent ( Fig. 1 ) that is phosphorylated by hexokinase to 2-DG-p, which cannot be further metabolized by the glycolytic pathway, leading to depleting of cellular ATP [8] . However, its efficacy remains limited because of the systemic toxicity induced by the high concentrations [9] .
Another prominent feature of cancer cells has been their prolonged resistance to mitochondrial apoptosis, which renders them capable of indefinite growth [4, 10] . Mitochondria generate most of the cellular supply of chemical energy in the form of ATP. Apart from ATP synthesis, the mitochondrion is also involved in a wide array of cellular processes such as cell metabolism, growth, cell death, differentiation, and aging [11] . It is a central player in crucial cellular functions and the established role of mitochondrial defects in tumorigenesis has led to the mitochondria being a prime target for targeted anticancer treatment strategies [12] .
This understanding of the molecular mechanisms and implications of both mitochondrial pathways and glycolytic metabolism in cancer has fueled an increase in research focusing on drugs that target both pathways [13] . Mito-carboxy proxyl (Mito-CP), a five-membered nitroxide ( Fig. 1 ) that is covalently linked to a lipophilic triphenylphosphonium cation, is a mitochondria-targeted antioxidant. Mito-CP accumulates in the mitochondria because of its lipophilic nature, chain length, and negative mitochondrial membrane potential [14] . Previous studies have shown that Mito-CP and Mito-Q, another mitochondria-targeted antioxidant, effectively inhibited the proliferation of breast cancer cell lines MCF-7 and MDA-MB-231 and colon cancer cell line HCT-116 [15, 16] . Recently, Mito-CP has been used in combination with glycolysis inhibitor 2-DG to eradicate breast cancer cells. This study has highlighted the ability of this combination treatment to target both mitochondrial and glycolytic pathways and effectively inhibit the growth of breast cancer both in vitro and in mouse models [17] .
In this study, we evaluate the synergistic effects of mitochondrial-targeted antioxidant, Mito-CP, and glycolysis inhibitor 2-DG in HepG2, a human HCC cell line. Primary hepatocytes were used as control cells to determine whether combination treatment induced toxicity or potential side effects to the normal liver.
Materials and methods

Cell culture
HepG2, a hepatocarcinoma cell line (ATCC, Manassas, Virginia, USA), was maintained in Eagle's Minimum Essential Medium (ATCC) containing 10% fetal bovine serum (Life Technologies, Carlsbad, California, USA). Cells were grown to about 70-80% confluence, trypsinized with TrypLE (Life Technologies), and seeded 12-18 h before treatment in all the experiments.
Cryopreserved primary human hepatocytes (Life Technologies) were thawed immediately, washed with CHRM medium (Life Technologies), counted, and adjusted to a density of 0.6 Â 10 6 cells/ml with hepatocyte plating medium supplemented with plating supplements (Life Technologies). The cells were then seeded in collagencoated 96-well plates (Life Technologies) and placed in the incubator for 4-6 h for cell attachment and formation of a monolayer. Then, the plate was shaken to loosen debris. The medium was aspirated and replaced with hepatocyte maintenance medium supplemented with maintenance supplements, and placed in an incubator at 371C and 5% CO 2 overnight before treatment in all the experiments conducted in this study. 
Cell viability assay
HepG2 cells were seeded at a density of 20 000 cells/well in 96-well plates and incubated for 12-18 h under 5% CO 2 at 371C. Following incubation, cells were treated with increasing concentrations of Mito-CP (1-4 mmol/l final concentration) and 2-DG (1-5 mmol/l final concentration) both individually and in combination for a period of 24 h and then the methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay was carried out (Promega, Madison, Wisconsin, USA). As a control, primary hepatocytes were also seeded in collagen-coated 96-well plates and treated with the same concentrations of Mito-CP and 2-DG for a period of 24 h; then, the viability was determined using the MTT assay. Experiments were conducted in triplicate and data were plotted as mean±SEM.
Cytotoxicity assay
HepG2 and primary hepatocyte cells were seeded at a density of 16 000 cells/well in 96-well plates and incubated overnight. The cells were then treated with Mito-CP and 2-DG as described above. For the cytotoxicity assay, YOYO-1 (Life Technologies) was diluted in cell culture medium and added to a final concentration of 0.1 mmol/l to both experimental and control wells. YOYO-1 is a cell-impermeant cyanine dimer nucleic acid stain that can only enter cells with a compromised plasma membrane and fluorescently stain the nuclear DNA [18] . By adding YOYO-1 to cells, we measured in real time the increase in YOYO-1 fluorescence, that is cell toxicity corresponding to treatment with Mito-CP and 2-DG. The treated plates were placed in an Incucyte FLR imaging system and the YOYO-1 fluorescence was measured every 2 h for a period of 24 h. Following the 24-h incubation period, end point analysis was carried out to measure the total number of DNA-containing objects by treating cells with 0.0625% Triton X-100 to permeabilize the cell membrane. The plate was further incubated for 1-2 h to allow staining of nuclear DNA by YOYO-1.
Object counting analysis was carried out using the Incucyte FLR software (Essen Biosciences, Ann Arbor, Michigan, USA) to calculate the total number of YOYO-1 fluorescence-positive cells and total DNA-containing objects (end point). The cytotoxicity index was calculated by dividing the number of YOYO-1 fluorescencepositive objects by the total number of DNA-containing objects for each treatment group.
ATP assay
HepG2 cells and primary hepatocytes were seeded at a density of 20 000 cells/well in 96-well plates and placed in the incubator overnight as described earlier. The cells were then treated with increasing concentrations of Mito-CP (1-4 mmol/l final concentration) and 2-DG (1-5 mmol/l final concentration) both individually and in combination for a period of 6 h.
The ATP levels were measured using the ATP bioluminescent somatic cell assay kit (Sigma Aldrich) according to the manufacturer's instructions. Following the measurement of ATP, 20 ml of the cell lysates was used to assay the protein concentration in all the treatment groups by the Bradford assay. The total ATP levels were normalized with respect to the total protein concentration in each well. Experiments were conducted in triplicate and data were plotted as mean±SEM.
Caspase 3/7 apoptosis assay
HepG2 and primary hepatocytes cells were seeded as described earlier. The next day, cells were treated with Mito-CP and 2-DG dissolved to appropriate concentrations in cell culture medium. Caspase 3/7 apoptosis reagent (Essen Biosciences) was diluted in cell culture medium and added to a final concentration of 5 mmol/l to both experimental and control wells. Caspase 3/7 apoptosis reagent (Essen Biosciences) is an inert nonfluorescent substrate that can enter cells by freely crossing the cell membrane. Once inside cells, this molecule becomes cleaved by the activated caspase 3/7
in cells to release a fluorescent green DNA labeling dye. By treating cells with this reagent, we measured in real time the increases in caspase 3/7 apoptotic activity in response to increasing concentrations of combination treatment with Mito-CP and 2-DG. 
Results
Effect of Mito-CP and 2-DG on the cell viability of HepG2 cells and primary hepatocytes
The results of the MTT assay after 24-h incubation with increasing concentrations of Mito-CP and 2-DG in HepG2 cells and primary hepatocytes are shown in Fig. 2a . Both Mito-CP and 2-DG moderately decreased (approximately at a 20% higher dose) the viability of HepG2 cells in a dose-dependent manner. Treatment with up to 5 mmol/l 2-DG alone or up to 4 mmol/l of Mito-CP alone did not visibly reduce the viability of HepG2 cells. Most importantly, treatment with 2 mmol/l Mito-CP and 1 mmol/l 2-DG in combination led to an increased reduction in HepG2 cell viability by 50% ( Fig. 2a ). However, primary cells remained unaffected at all individual and combination treatment doses, maintaining a cell viability of greater than 80% ( Fig. 2a ).
Effect of Mito-CP and 2-DG on ATP levels of HepG2 cells and primary hepatocytes
To further confirm the growth inhibition by the combination treatment, we measured the intracellular ATP levels after treatment. After treatment with Mito-CP and 2-DG (6 h), the ATP levels of HepG2 cells reduced significantly with increasing treatment concentrations ( Fig. 2b ). Whereas treatment with 2 mmol/l Mito-CP reduced the ATP concentration to 70% of the control cell ATP levels, a combination of 2 mmol/l Mito-CP and 1 mmol/l 2-DG further decreased it down to 40% of the control cell ATP levels. The protein concentrations of HepG2 cells remained fairly stable, except for a slight decrease at higher concentrations, indicating that the cells remained viable at the time when the ATP levels were measured (Fig. 2b) . ATP levels and protein concentration remained unchanged in primary hepatocytes following a 6-h treatment with both individual and combination doses of Mito-CP and 2-DG ( Fig. 2c ).
Cytotoxic effects of Mito-CP and 2-DG on HepG2 cells and primary hepatocytes
To determine the status of cytotoxic effects during the treatment, real-time increases in the cytotoxic effects of Mito-CP and 2-DG on HepG2 cells were monitored using the YOYO-1 cell-impermeant nucleic acid stain and the Incucyte FLR imaging system (Fig. 3a) . We observed a steady increase in YOYO-1 fluorescence (caused by binding of the dye to nucleic acid) that began at about 10 h after treatment and peaked at 24 h on combination treatment with Mito-CP and 2-DG. Cells treated individually with Mito-CP or 2-DG did not induce an increase in the YOYO-1 fluorescence signal, proving the synergistic effects of the compounds in inhibiting HCC. The cytotoxicity index of HepG2 cells mirrors the realtime data showing marked increases with combination treatment (Fig. 3b ). The cytotoxic index of primary hepatocytes remained negligible in all treatment groups, being consistent with the results of the cell viability assay (Fig. 3b ). On the basis of the results from cell viability, cytotoxicity assay, and measurement of ATP levels, we confirmed that Mito-CP in combination with 2-DG treatment potentiated the reduction of HepG2 cellular growth compared with single-agent treatment. Furthermore, the combination treatment appears to be synergic.
Combined treatment with Mito-CP and 2-DG induces apoptosis in HepG2 cells
To examine whether Mito-CP and 2-DG inhibit the survival of HepG2 cells by triggering the apoptotic pathway, we measured the increase in caspase 3/7 activity following treatment. Real-time increases in caspase 3/7 activity were monitored using the Incucyte FLR imaging system. Caspase 3/7 activity increases consistently in both the combination treatment groups (2 mmol/l Mito-CP + 5 mmol/l 2-DG and 4 mmol/l Mito-CP + 5 mmol/l 2-DG) with time. The real-time object-counting analysis curve shows initiation of apoptotic activity at about 11 h after treatment and peaks at 22 h. Individual treatments with Mito-CP or 2-DG showed no increase in caspase 3/7 activity. The apoptotic index (as determined from the end point assay) is the highest in the combination treatment groups (Fig. 4a) and is thus consistent with the synergistic trend and real-time caspase 3/7 activity for HepG2 cells. As predicted on the basis of our MTT data, primary cells did not show caspase 3/7 activity. The apoptotic index remained fairly low in all treatment groups, with a minor increase in the groups treated with a higher concentration of Mito-CP (4 mmol/l) (Fig. 4b) .
To further confirm that HepG2 cell growth is inhibited by activation of apoptosis, we assessed the expression of proapoptotic and antiapoptotic proteins in response to treatment with Mito-CP and 2-DG by western blot (Fig. 4c ). The combination of Mito-CP and 2-DG induced apoptosis by activating caspases-3 and 7 by reducing the procaspases more than either drug alone. To confirm the function of caspase activity, we examined the expression level of total PARP. As shown in Fig. 4c , the expression of PARP protein was completely reduced in the combination treatment. Furthermore, the level of antiapoptotic protein survivin was also reduced significantly compared with either treatment alone. A Bcl-2 family member, Bcl xL , and Mcl-1 localize to the mitochondria and inhibit apoptosis. In the combination treatment, the levels of these proteins were reduced significantly. The level of Bax protein is not changed with treatment.
Discussion
In the present study, we show that Mito-CP, a mitochondrial-targeted antioxidant, in conjunction with a glycolysis inhibitor, 2-DG, caused a selective and synergistic cytotoxicity in HCC cells. Nitroxides have been used in cancer research as therapeutics, oximetric, and imaging agents. In a previous study, the nitroxide 5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl has been shown to ameliorate tumorigenic propensity in mice [18] .
Another study highlights the potential use of tempol (nitroxide) as a therapeutic agent against malignant gliomas [19] . 2-DG, in contrast, is a glycolysis inhibitor that has been studied extensively over the years for its cancer-inhibiting properties. Recently, several studies have used 2-DG in innovative combination therapies and synergistic treatment strategies against a broad spectrum of cancers. Recently, 2-DG was used in conjunction with Bcl2 antagonists to study the therapeutic potential of this combination against prostate cancer [20] . Further, 2-DG has also been used in combination with AMPK agonists to study its ability to dual target energy pathways and induce growth inhibition in multiple types of cancer [21] .
We hypothesized that using Mito-CP and 2-DG (whose anticancer properties have been established in a wide range of cancers) in conjunction might enable us to preferentially target and inhibit HCC cell proliferation at a much lower concentration than when used individually. As this combination would directly target the site of energy generation in the cell and because of the previously established differences in the energy production mechanisms between cancer and normal cells, this combination might prove advantageous for specific targeted inhibition of HCC. Furthermore, a similar strategy using mitochondrial-targeted nitroxides with cytotoxic chemotherapeutic compounds has resulted in enhanced anticancer effects against breast cancer cells while being nontoxic to normal cells [22] .
The results of this preliminary study confirm that 2-DG and Mito-CP in conjunction induce cytotoxicity and inhibit the proliferation of HepG2 cells in a possible synergistic manner while causing no measureable cytotoxicity or change in the viability of primary human hepatocytes ( Fig. 2a and Fig. 3 ). Previous studies have shown the cytotoxic effects of 2-DG alone in various T-cell and B-cell lymphoma cell lines [23, 24] . Cytotoxic effects of 2-DG in combination with apoptosis-inducing ligands in melanoma cells have been reported [23] . However, 2-10-fold higher doses of 2-DG have been used in these studies compared with the present study [23, 24] . Using Mito-CP in combination with 2-DG, we are able to reduce the concentration of 2-DG by 2-10-fold compared with previous studies and still induce a significant reduction in the viability of HepG2 cells. Thus, this combination may provide reduced toxicity to normal liver as a valuable advantage.
The fact that a reduction in the ATP level compared with either treatment alone or with treated primary hepatocyte showed no change in the total protein levels in all groups strongly suggests that the decrease in ATP levels in HepG2 cells is solely the effect of treatment with Mito-CP and 2-DG. On the basis of this, we can anticipate that the use of reduced doses in combination with decreased toxicity to the normal liver may be a potential treatment option for the HCC patient ( Fig. 2b and c) .
Multicellular organisms maintain a delicate balance between the mechanisms of cell survival and death for normal tissue maintenance and development. Tumor development occurs when intrinsic deregulation in the apoptotic mechanism is triggered in certain cells, which enables continued growth [25] . Activation of a set of cysteine proteases termed caspases, which further cleave cell substrates, is a key step in the apoptotic process [26] . Caspases 3 and 7 are two such effector caspases whose activation indicates the cells irreversible commitment to apoptosis and are therefore reliable markers for apoptosis [27] . The synergistic increase in caspase 3/7 activity (Fig. 4) is indicates that Mito-CP and 2-DG in combination trigger apoptosis to induce HepG2 cell death in a time-dependent and dose-dependent manner. This was confirmed by western analysis for the expression of these proteins (Fig. 4c ). The increase in apoptotic activity is consistent and parallel in time to the cytotoxicity observed in HepG2 cells. However, compared with HepG2 cells, the apoptotic activity in primary hepatocytes remained negligible (Fig. 4b ).
In summary, we have shown that Mito-CP and 2-DG increase cytotoxicity and decrease the viability of HepG2 cells compared with the control as well as primary hepatocytes. This combination treatment invades the ATP-producing mechanism and is associated with induction of apoptosis in HepG2 cells while causing no measurable change in the viability or energy-producing capabilities in primary hepatocytes. This provides evidence for further study into the use of this combination therapy against HCC.
